Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with RET -altered solid tumors in the US.

Autor:	Bhandari NR; Eli Lilly and Company, Indianapolis, IN, USA., Gilligan AM; Eli Lilly and Company, Indianapolis, IN, USA., Myers J; Medical Decision Modeling Inc, Indianapolis, IN, USA., Ale-Ali A; Eli Lilly and Company, Indianapolis, IN, USA., Smolen L; Medical Decision Modeling Inc, Indianapolis, IN, USA.
Jazyk:	angličtina
Zdroj:	Journal of medical economics [J Med Econ] 2024 Jan-Dec; Vol. 27 (1), pp. 348-358. Date of Electronic Publication: 2024 Mar 06.
DOI:	10.1080/13696998.2024.2317120
Abstrakt:	Objective: To estimate the potential budget impact on US third party payers (commercial or Medicare) associated with addition of selpercatinib as a tumor-agnostic treatment for patients with Rearranged during Transfection ( RET )-altered solid tumors. Methods: An integrated budget impact model (iBIM) with 3-year (Y) time horizon was developed for 19 RET -altered tumors. It is referred to as an integrated model because it is a single model that integrated results across multiple tumor types (as opposed to tumor-specific models developed traditionally). The model estimated eligible patient populations and included tumor-specific comparator treatments for each tumor type. Estimated annual total costs (2022USD, $) included costs of drug, administration, supportive care, and toxicity. For a one-million-member plan, the number of patients with RET -altered tumors eligible for treatment, incremental total costs, and incremental per-member per-month (PMPM) costs associated with introduction of selpercatinib treatment were estimated. Uncertainty associated with model parameters was assessed using various sensitivity analyses. Results: Commercial perspective estimated 11.68 patients/million with RET -altered tumors as treatment-eligible annually, of which 7.59 (Y1), 8.17 (Y2), and 8.76 (Y3) patients would be selpercatinib-treated (based on forecasted market share). The associated incremental total and PMPM costs (commercial) were estimated to be: $873,099 and $0.073 (Y1), $2,160,525 and $0.180 (Y2), and $2,561,281 and $0.213 (Y3), respectively. The Medicare perspective estimated 55.82 patients/million with RET -altered tumors as treatment-eligible annually, of which 36.29 (Y1), 39.08 (Y2), and 41.87 (Y3) patients would be selpercatinib-treated. The associated incremental total and PMPM costs (Medicare) were estimated to be: $4,447,832 and $0.371 (Y1), $11,076,422 and $0.923 (Y2), and $12,637,458 and $1.053 (Y3), respectively. One-way sensitivity analyses across both perspectives identified drug costs, selpercatinib market share, incidence of RET , and treatment duration as significant drivers of incremental costs. Conclusions: Three-year incremental PMPM cost estimates suggest a modest impact on payer-budgets associated with introduction of tumor-agnostic selpercatinib treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu